| Document |
Document Title |
|
WO/2022/166796A1 |
Disclosed are a novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor, a preparation method therefor and use thereof. The novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor is a compound as represen...
|
|
WO/2022/166980A1 |
The present invention belongs to the field of medicine, and in particular relates to a heteroarylpiperidine derivative, a pharmaceutical composition and use thereof. The heteroarypiperidine derivative as shown in formula (I) provided by ...
|
|
WO/2022/166440A1 |
Provided is a method for preparing a moxifloxacin intermediate, (S,S)-2,8-diazabicyclo[4,3,0]nonane, which relates to the technical field of organic synthesis. By means of the present invention, methyl 2-chloromethyl nicotinate is first ...
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/166983A1 |
The present invention belongs to the field of medicine, and in particular relates to heteroarylopiperidine derivative, and a pharmaceutical composition thereof and the use thereof. The heteroarylopiperidine derivative as shown in formula...
|
|
WO/2022/166468A1 |
A heterocyclic compound that acts as a BTK inhibitor, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a compound represented by general formula (I) and a pharmaceutica...
|
|
WO/2022/169780A1 |
The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling...
|
|
WO/2022/169921A1 |
The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said comp...
|
|
WO/2022/166879A1 |
The present invention relates to a benzo seven-membered ring bifunctional compound and an application thereof, and in particular to a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof. The compound can b...
|
|
WO/2022/166436A1 |
The present invention relates to the technical field of organic synthesis, and provides a method for preparing a Moxifloxacin intermediate (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane. According to the present invention, azaphthalide is use...
|
|
WO/2022/166974A1 |
A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibit...
|
|
WO/2022/166920A1 |
The present invention relates to a pyrrolopyridazine compound as represented by a formula (I) or a pharmaceutically acceptable salt thereof, and also relates to a pharmaceutical preparation, a pharmaceutical composition and the use there...
|
|
WO/2022/166441A1 |
The present invention relates to the technical field of organic synthesis, in particular, to a preparation method for 2-acetyl-1,10-phenanthroline. The preparation method provided in the present invention comprises the following steps: i...
|
|
WO/2022/168122A1 |
The present invention relates to various processes for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4(6-(6-((6-methoxypyridin-3-
yl)methyl)-3,6-diazabicyclo[3.1.1] heptan-3-yl)pyridin-3yl)pyrazolo[1,5-a]pyridine-3-carbonit
rile, ...
|
|
WO/2022/167503A1 |
The present invention relates to a compound or a combination of compounds which can be used as anti-fungal agents directed against plant pathogenic basidiomycete fungi, and especially for inhibiting the virulence of corn smut fungus Usti...
|
|
WO/2022/166749A1 |
Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...
|
|
WO/2022/166844A1 |
Tricyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein each variable is as defined in the description.
|
|
WO/2022/169974A1 |
The present invention relates to pharmaceutical compounds, compositions, combinations, and methods, especially as they are related to compositions and methods for the treatment and/or prevention of conditions such as gout that are associ...
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/169948A1 |
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
|
|
WO/2022/166991A1 |
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/166442A1 |
The present invention relates to the technical field of organic synthesis, and in particular, to a preparation method for 2-acetyl-1,10-phenanthroline. The preparation method provided in the present invention comprises the following step...
|
|
WO/2022/169840A1 |
A combined cancer therapy comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, an immune checkpoint inhibitor, and optionally a radiotherapy.
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/106469A3 |
The present invention provides compounds of formula (I), for the treatment of an infection in warm-blooded animal caused by endoparasites, more preferably a helminthic infection, even more preferably a heartworm infection. Exemplary comp...
|
|
WO/2022/166592A1 |
The present invention relates to a substituted pyrimidopyridone inhibitor, and a preparation method therefor and the use thereof. Specifically, the compound has a structure as shown in formula (I). Further disclosed are a method for prep...
|
|
WO/2022/166810A1 |
The present disclosure relates to a fused azatricyclic derivative, a preparation method therefor, and an application thereof in medicine. In particular, the present disclosure relates to a fused azatricyclic derivative represented by gen...
|
|
WO/2022/166845A1 |
The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug, and mixture thereof...
|
|
WO/2022/166599A1 |
A new use of PQQ and a derivative thereof. PQQ can effectively alleviate or treat primary dysmenorrhea, secondary dysmenorrhea and abnormal menstruation. After being treated with PQQ, the following effects can be achieved for patients: 1...
|
|
WO/2022/167627A1 |
The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds accord...
|
|
WO/2022/169019A1 |
The present invention relates to a novel compound for photodynamic cancer therapy, a composition comprising same, and a photodynamic cancer therapy method, and more specifically to: a novel photosensitizer compound which is based on NpIm...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/169184A1 |
The present invention relates to a novel compound and an organic light-emitting element comprising the novel compound in one or more organic layers to thus be highly efficient.
|
|
WO/2022/165530A1 |
Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (II) and compounds of formula (III), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are pr...
|
|
WO/2022/165092A1 |
The present disclosure provides biomarkers and methods that are useful in treating, screening, and/or evaluating treatment of fibrotic diseases with methyl (Z)-3-(((4-(N-methyl-2- (4-methylpiperazin-l-yl)acetamido)phenyl)amino)(phenyl)me...
|
|
WO/2022/165402A1 |
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least o...
|
|
WO/2022/162690A1 |
The present invention relates to process for the preparation of Ripretinib and intermediates thereof. The present invention also relates to the process for the preparation of Ripretinib intermediates. The present invention relates to sol...
|
|
WO/2022/165529A1 |
Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharma...
|
|
WO/2022/164934A1 |
The present disclosure provides methods, compounds and compositions that are relevant to DNA-repair and DNA-repair proteins such as tyrosyl-DNA phosphodiesterase 1 (TDP1) and type I topoisomerase (TOP1).
|
|
WO/2022/160015A1 |
The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic...
|
|
WO/2022/160869A1 |
The present disclosure relates to the technical field of chelating agents, and in particular, to a bifunctional macrocyclic chelate, a conjugate, a metal complex and use thereof. The bifunctional macrocyclic chelate is a compound as show...
|
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
|
WO/2022/162034A1 |
The present invention provides compounds of formula I or II: (I) wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the ...
|
|
WO/2022/160066A1 |
The specification relates to a crystalline Latrepirdine dihydrochloride, Form DMB-I, method of its preparation, pharmaceutical composition containing it and its uses.
|
|
WO/2022/161489A1 |
Disclosed in the present invention are a pentaheterocyclic compound, a preparation method therefor and use thereof. In particular, disclosed in the present invention are a compound as shown in formula I, a pharmaceutically acceptable sal...
|
|
WO/2022/164835A1 |
Described herein are compositions and their use in methods and pharmaceutical compositions for inhibiting the binding between Yes-associated protein and TEA domain. Also, described herein are methods of using said compositions capable of...
|
|
WO/2022/161496A1 |
The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compound...
|
|
WO/2022/161493A1 |
An aza-ergoline derivative and a preparation method therefor and an application thereof. The derivative has a structure as shown in formula (I). The aza-ergoline derivative has good affinity, agonistic activity or selectivity to a dopami...
|
|
WO/2022/161222A1 |
The present invention relates to a heterocyclic SHP2 inhibitor, a preparation method therefor, and a use thereof. Specifically, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, ester, ster...
|
